Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections

Molecular Immunology

Volumn 53, Issue 1-2, 2013, Pages 149-160

  Mohit, Elham ^a   Bolhassani, Azam ^a   Zahedifard, Farnaz ^a   Seyed, Negar ^a   Eslamifar, Ali ^a   Taghikhani, Mohammad ^b   Samimi Rad, Katayoun ^c   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

E7; Gp96; HPV DNA vaccine; IP 10; PEI600 Tat; RANTES

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 96; INTERLEUKIN 2; INTERLEUKIN 5; RANTES; TRANSACTIVATOR PROTEIN; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; FUSION GENE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; LYMPH NODE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; ZETA POTENTIAL;

ANIMALS; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, TAT; GENE TRANSFER TECHNIQUES; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYETHYLENEIMINE; TRANSFECTION; VACCINES, DNA;

HUMAN PAPILLOMAVIRUS; MUS;

EID: 84865328245     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.07.011     Document Type: Article

References (59)

1. Akinc A., Thomas M., Klibanov A.M., Langer R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. Journal of Gene Medicine 2005, 7:657-663.
2. Alexis F., Lo S., Wang S. Covalent attachment of low molecular weight poly (ethyleneimine) improves Tat peptide mediated gene delivery. Advanced Materials 2006, 18:2174-2178.
3. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., Kleinman H.K., Reaman G.H., Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. Journal of Experimental Medicine 1995, 182:155-162.
4. Aravindaram K., Yu H.H., Lan C.W., Wang P.H., Chen Y.H., Chen H.M., Yagita H., Yang N.S. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma. Gene Therapy 2009, 16:1329-1339.
5. Arenberg D.A., White E.S., Burdick M.D., Strom S.R., Strieter R.M. Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Immunology and Immunotherapy 2001, 50:533-538.
6. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., Gallino G., Piris A., Cattelan A., Lazzari I., Carrabba M., Scita G., Santantonio C., Pilla L., Tragni G., Lombardo C., Arienti F., Marchiano A., Queirolo P., Bertolini F., Cova A., Lamaj E., Ascani L., Camerini R., Corsi M., Cascinelli N., Lewis J.J., Srivastava P., Parmiani G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. Journal of Clinical Oncology 2002, 20:4169-4180.
7. Binder R.J., Han D.K., Srivastava P.K. CD91: a receptor for heat shock protein gp96. Nature Immunology 2000, 1:151-155.
8. Biswas C., Sriram U., Ciric B., Ostrovsky O., Gallucci S., Argon Y. The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells. International Immunology 2006, 18:1147-1157.
9. Bolhassani A., Ghasemi N., Servis C., Taghikhani M., Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Delivery 2009, 16:196-204.
10. Bolhassani A., Ghasemi N., Servis C., Taghikhani M., Rafati Yazdi S. Comparison of two delivery systems efficiency by using polyethylenimine (PEI) for plasmid HPV16 E7 DNA transfection into COS-7 cells. Modarres Journal of Medical Science 2008, 11:15-19.
11. Bolhassani A., Mohit E., Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Human Vaccines 2009, 5:671-689.
12. Bolhassani A., Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Review of Vaccines 2008, 7:1185-1199.
13. Bolhassani A., Zahedifard F., Taghikhani M., Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008, 26:3362-3370.
14. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective International biological study on cervical cancer (IBSCC) Study Group. Journal of the National Cancer Institute 1995, 87:796-802.
15. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7297-7301.
16. Brooks H., Lebleu B., Vives E. Tat peptide-mediated cellular delivery: back to basics. Advanced Drug Delivery Reviews 2005, 57:559-577.
17. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., Wu T.C. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Research 2000, 60:1035-1042.
18. Christensen J.E., de Lemos C., Moos T., Christensen J.P., Thomsen A.R. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. Journal of Immunology 2006, 176:4235-4243.
19. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
20. Ferrari S., Moro E., Pettenazzo A., Behr J.P., Zacchello F., Scarpa M. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Therapy 1997, 4:1100-1106.
21. Frauenschuh A., DeVico A.L., Lim S.P., Gallo R.C., Garzino-Demo A. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 2004, 23:546-554.
22. Giannouli C., Brulet J.M., Gesche F., Rappaport J., Burny A., Leo O., Hallez S. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Research 2003, 23:3523-3531.
23. Hung C.F., Monie A., Alvarez R.D., Wu T.C. DNA vaccines for cervical cancer: from bench to bedside. Experimental and Molecular Medicine 2007, 39:679-689.
24. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
25. Ji H., Chang E.Y., Lin K.Y., Kurman R.J., Pardoll D.M., Wu T.C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. International Journal of Cancer 1998, 78:41-45.
26. Jiang X.B., Lu X.L., Hu P., Liu R.E. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 2009, 27:6210-6216.
27. Kang T.H., Bae H.C., Kim S.H., Seo S.H., Son S.W., Choi E.Y., Seong S.Y., Kim T.W. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency. Journal of Gene Medicine 2009, 11:889-898.
28. Kang T.H., Kim K.W., Bae H.C., Seong S.Y., Kim T.W. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. International Journal of Cancer 2011, 128:702-714.
29. Kim S.J., Lee C., Lee S.Y., Kim I., Park J.S., Sasagawa T., Ko J.J., Park S.E., Oh Y.K. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES. Gene Therapy 2003, 10:1268-1273.
30. Krathwohl M.D., Anderson J.L. Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model. Vaccine 2006, 24:2987-2993.
31. Lapteva N., Aldrich M., Weksberg D., Rollins L., Goltsova T., Chen S.Y., Huang X.F. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. Journal of Immunotherapy 2009, 32:145-156.
32. Lapteva N., Huang X.F. CCL5 as an adjuvant for cancer immunotherapy. Expert Opinion on Biological Therapy 2010, 10:725-733.
33. Lavergne E., Combadiere C., Iga M., Boissonnas A., Bonduelle O., Maho M., Debre P., Combadiere B. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. Journal of Immunology 2004, 173:3755-3762.
34. Li H., Zhou M., Han J., Zhu X., Dong T., Gao G.F., Tien P. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. Journal of Immunology 2005, 174:195-204.
35. Li H.T., Yan J.B., Li J., Zhou M.H., Zhu X.D., Zhang Y.X., Tien P. Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World Journal of Gastroenterology 2005, 11:2858-2863.
36. Li Y., Subjeck J., Yang G., Repasky E., Wang X.Y. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 2006, 24:5360-5370.
37. Lu X.L., Jiang X.B., Liu R.E., Zhang S.M. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 2008, 26:5352-5357.
38. Luster A.D., Leder P. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. Journal of Experimental Medicine 1993, 178:1057-1065.
39. Ma K., Xu W., Shao X., Yanyue Hu L., Xu H., Yuan Z., Zheng X., Xiong S. Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells. Antiviral Research 2007, 76:140-149.
40. Mazzaferro V., Coppa J., Carrabba M.G., Rivoltini L., Schiavo M., Regalia E., Mariani L., Camerini T., Marchiano A., Andreola S., Camerini R., Corsi M., Lewis J.J., Srivastava P.K., Parmiani G. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clinical Cancer Research 2003, 9:3235-3245.
41. Mohit E., Bolhassani A., Zahedifard F., Taslimi Y., Rafati S. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL/6 mouse model. Scandinavian Journal of Immunology 2012, 75:27-37.
42. Narvaiza I., Mazzolini G., Barajas M., Duarte M., Zaratiegui M., Qian C., Melero I., Prieto J. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. Journal of Immunology 2000, 164:3112-3122.
43. Oki Y., McLaughlin P., Fayad L.E., Pro B., Mansfield P.F., Clayman G.L., Medeiros L.J., Kwak L.W., Srivastava P.K., Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 2007, 109:77-83.
44. Ramirez S.R., Singh-Jasuja H., Warger T., Braedel-Ruoff S., Hilf N., Wiemann K., Rammensee H.G., Schild H. Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress and Chaperones 2005, 10:221-229.
45. Riedl P., Reimann J., Schirmbeck R. Peptides containing antigenic and cationic domains have enhanced. Journal of Molecular Medicine (Berlin) 2004, 82:144-152.
46. Robinson S.C., Scott K.A., Balkwill F.R. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. European Journal of Immunology 2002, 32:404-412.
47. Segal B.H., Wang X.Y., Dennis C.G., Youn R., Repasky E.A., Manjili M.H., Subjeck J.R. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discovery Today 2006, 11:534-540.
48. Sin J., Kim J.J., Pachuk C., Satishchandran C., Weiner D.B. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Journal of Virology 2000, 74:11173-11180.
49. Singh-Jasuja H., Hilf N., Scherer H.U., Arnold-Schild D., Rammensee H.G., Toes R.E., Schild H. The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress and Chaperones 2000, 5:462-470.
50. Singh-Jasuja H., Toes R.E., Spee P., Munz C., Hilf N., Schoenberger S.P., Ricciardi-Castagnoli P., Neefjes J., Rammensee H.G., Arnold-Schild D., Schild H. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. Journal of Experimental Medicine 2000, 191:1965-1974.
51. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nature Reviews Immunology 2002, 2:185-194.
52. Su J.H., Wu A., Scotney E., Ma B., Monie A., Hung C.F., Wu T.C. Immunotherapy for cervical cancer: research status and clinical potential. BioDrugs 2010, 24:109-129.
53. Ulmer J.B., Wahren B., Liu M.A. Gene-based vaccines: recent technical and clinical advances. Trends in Molecular Medicine 2006, 12:216-222.
54. Welters M.J., Kenter G.G., de Vos van Steenwijk P.J., Lowik M.J., Berends-van der Meer D.M., Essahsah F., Stynenbosch L.F., Vloon A.P., Ramwadhdoebe T.H., Piersma S.J., van der Hulst J.M., Valentijn A.R., Fathers L.M., Drijfhout J.W., Franken K.L., Oostendorp J., Fleuren G.J., Melief C.J., van der Burg S.H. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:11895-11899.
55. Weng Y., Siciliano S.J., Waldburger K.E., Sirotina-Meisher A., Staruch M.J., Daugherty B.L., Gould S.L., Springer M.S., DeMartino J.A. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. Journal of Biological Chemistry 1998, 273:18288-18291.
56. Xin K.Q., Lu Y., Hamajima K., Fukushima J., Yang J., Inamura K., Okuda K. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clinical Immunology 1999, 92:90-96.
57. Yan J., Liu X., Wang Y., Jiang X., Liu H., Wang M., Zhu X., Wu M., Tien P. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. Journal of Gene Medicine 2007, 9:107-121.
58. Yang L.L., Ping C., Luo S., Li J., Liu K., Hu H.Z., Wei Y.Q. CXCL10 gene therapy efficiently inhibited the growth of cervical carcinoma based on the antiangiogenic and antiviral activity. Biotechnology and Applied Biochemistry 2009.
59. Yang X., Chu Y., Wang Y., Zhang R., Xiong S. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. Journal of Leukocyte Biology 2006, 80:1434-1444.